Previous 10 | Next 10 |
Decibel is a category leader in developing new medicines for hearing and balance disorders. The company's lead asset, DB-OTO, has several upcoming catalysts over the next 18 months that can validate Decibel's platform. With a unique business model, Decibel is a compelling investme...
Companies engaged in developing therapies for Alzheimer's disease were among the best performing biotech stocks in the first half of the year.Cassava Sciences ([[SAVA]] -1.7%) was the best performing biotech stock in the half, with a return in the period of 1166%.A phase 3 trial of its Alzhei...
NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Frequency, Inc. (“Frequency” or “WPG”) (NASDAQ: FREQ) in the United States District Court for the District of Massachusetts on b...
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will pr...
Frequency Therapeutics, Inc., (Nasdaq: FREQ) today shared a statement from David L. Lucchino, Frequency’s Chief Executive Officer, in support of the Hearing Loss Association of America (HLAA) and its efforts to advance the voice of the patient in leading the first-ever Externally...
Frequency Therapeutics (FREQ): Q1 GAAP EPS of -$0.60 misses by $0.88.Revenue of $4.7M (-35.3% Y/Y) misses by $3.43M.Shares -0.79% PM.Press Release For further details see: Frequency Therapeutics EPS misses by $0.88, misses on revenue
Data From Recent FX-322 Clinical Readouts, Including New Data from Phase 1b Study in Presbycusis (Age-Related Hearing Loss), Further Clarify Acquired Sensorineural Hearing Loss Target Patient Populations and Future Study Design Company Anticipates Initiation of New FX-322 Phas...
Biotech companies are about the riskiest investment someone can find in the stock market. They are often small, cash-strapped, and have a future inextricably tied to the success or failure of one clinical trial. For every Amgen , which has gone from a market cap of less than $1 bill...
I previously covered Frequency Therapeutics after the company had initiated a Phase 2a trial on the heels of a positive Phase 1/2 trial. This Phase 2a trial featured about three times more patients but failed to show the same promising efficacy in a recent data read-out. Managemen...
Frequency Therapeutics (NASDAQ: FREQ) is a clinical-stage biotech company currently conducting multiple clinical trials on FX-322, a hearing loss drug that is notably Frequency's only product in clinical development. Although final phase 2a results have yet to be released, interim r...
News, Short Squeeze, Breakout and More Instantly...
Frequency Therapeutics Inc. Company Name:
FREQ Stock Symbol:
NYSE Market:
Frequency Therapeutics, Inc. (Nasdaq: FREQ) today announced business updates and financial results for the second quarter ended June 30, 2023. In July, the Company announced that it entered into a definitive merger agreement with Korro Bio, Inc., a leading RNA editing company focused on the d...
2023-07-15 06:36:00 ET 3 Things to Know About Using Analyst Opinions for Trading Penny Stocks Trading penny stocks can be a thrilling venture, offering the potential for significant returns on small investments. One of the key aspects that can influence the success of such trades is the...
Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio’s wholly owned portfolio of RNA editing programs Lead program is a disease modifying therapy for patients with alpha-1 antitrypsin deficiency (AATD), with preclinical data showing an increase ...